Chong Kun Dang Enters the Hypertension Treatment Market: Should Investors Pay Attention to Telminuvo’s Approval? Chong Kun Dang’s newly developed hypertension treatment, Telminuvo, has received approval from the Ministry of Food and Drug Safety (MFDS). How will this news impact Chong Kun Dang Holdings’ stock price? This article delves into the significance of Telminuvo’s approval, … Read more
Korea BioNics’ Partial Vienox Lawsuit Win: An Investor Analysis Korea BioNics recently achieved a partial victory in the Vienox lawsuit. What implications does this hold for the company’s future? In this article, we delve into the significance of the ruling, analyze Korea BioNics’ fundamentals, and explore potential investment strategies. Read on to find out more. … Read more
Graphi: Poised for Growth or Facing Financial Peril? Graphi, a company making waves with its innovative shape memory transparent orthodontic device (SMA), has recently debuted on the KOSDAQ. However, its post-IPO financials have painted a concerning picture, leaving investors grappling with a crucial question: Does Graphi’s groundbreaking technology outweigh its significant financial challenges? This article … Read more
Chong Kun Dang’s New Hypertension Drug Telminuvo Approved: Is it an Investment Opportunity? Chong Kun Dang has secured a new growth engine with the domestic approval of Telminuvo (CKD-828). However, potential risks exist, including recent sluggish performance and intensified market competition. This article analyzes the implications of Telminuvo’s approval and key factors investors should consider, … Read more
Will Phacell Bio’s Dream of a Cancer Cure Become a Reality? Phacell Bio, a bio company attracting attention for its innovative anti-cancer drug development. The 2024 half-year report casts a shadow of continuous operating losses alongside hopeful news of positive clinical results and new drug approvals. Can Phacell Bio become a game changer in the … Read more
Korea United Pharm Secures New Growth Engine? Korea United Pharm has obtained approval for Siloduo SR, a combination drug for the treatment of chronic arterial occlusive disease. What does this news mean for investors? This article analyzes the potential impact of Siloduo SR’s launch on Korea United Pharm’s stock price and highlights key factors to … Read more
Can iCure Escape Delisting? iCure (175250)’s delisting review has been extended, increasing investor anxiety. Despite improved financials and growth in the cosmetics business, the possibility of delisting remains. This article analyzes iCure’s current situation, provides future outlook, and guides investors on the actions they should take. What Happened? On August 27, 2025, iCure announced that … Read more
Samchundang Pharm Decides to Dispose of Treasury Stock Worth 29.5 Billion Won! What’s the Investment Strategy? Samchundang Pharm’s announcement of treasury stock disposal is drawing attention from investors. Is this decision good news or bad news? This article closely analyzes the background and impact of the treasury stock disposal and presents key points investors should … Read more
Wonbiogen’s KRW 3 Billion Share Buyback: Impact on Stock Price? Biohealthcare company Wonbiogen has announced a KRW 3 billion share buyback program, representing approximately 7.22% of its market capitalization. What does this mean for investors, and how will it affect Wonbiogen’s stock price? This article analyzes the background, positive/negative impacts, and key information investors should … Read more
National Pension Service Bets on Yuhan Corp: What Should Investors Do? The National Pension Service (NPS), Korea’s largest pension fund, has changed its investment objective in Yuhan Corporation from ‘simple investment’ to ‘general investment’ and increased its stake. This can be interpreted as a positive signal for Yuhan’s future growth potential. This article analyzes the … Read more